Trials with medicinal products
ALCL-VBL (anaplastic large cell lymphoma) Clinical study into a new treatment for ALK+ anaplastic large cell lymphoma - open for inclusion
BIANCA (B-NHL) Clinical study with tisagenlecleucel in children and adolescents with B-cell non-Hodgkin lymphoma (B-NHL) - closed for inclusion
BrigaPED (tumors with ALK defect) Clinical study into the safety and effectiveness of brigatinib in children and young adults with ALK+ ALCL, IMT and other solid tumors with abnormalities in the ALK gene - open for inclusion
CA224-069 (cHL, NHL) Clinical study towards a new treatment (relatlimab with nivolumab) in children, adolescents and young adults with classical Hodgkin lymphoma (cHL) and non-Hodgkin lymphoma (NHL) - open for inclusion
CRISP (tumors with ALK/MET/ROS1 abnormalities) Clinical study of the safety and efficacy of the drug crizotinib in children, either alone or in combination with other drugs - open for inclusion
ESMART (different tumor types) Clinical study in children with cancer into the safety and efficacy of drugs matching a specific DNA alteration in the tumor - open for inclusion
HEM-iSMART subprotocol D (ALL/LBL) Clinical study of trametinib for children with relapsed or refractory leukemia or lymphoma with a RAS mutation - open for inclusion
Inotuzumab ITCC-059 (ALL/B-cell leukemia/lymphoma) Clinical study of the safety and efficacy of the drug Inotuzumab Ozogamicin (InO) in children with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) or other CD22-positive malignancies - open for inclusion
JCAR017-BCM-004 (B-ALL/B-NHL) Clinical study to evaluate the safety and efficacy of JCAR017 in children with a special type of leukemia (B-ALL) and non-Hodgkin’s lymphoma - open for inclusion
MK-3475-051 pembrolizumab (melanoma, solid tumor, lymphoma) Clinical study with the study drug MK-3475 in children with skin cancer (melanoma), solid tumor or lymphoma - open for inclusion
NIVO-ALCL (Anaplastic large cell lymphoma) Clinical study of a new treatment for ALK+ anaplastic large cell lymphoma (ALCL) - open for inclusion
Nivolumab CA 209-744 (Hodgkin-lymphoma) Clinical study of the safety, tolerability and efficacy of the drug nivolumab in combination with brentuximab vedotin in children with classic Hodgkin lymphoma - closed for inclusion
Ponatinib INCB084344 (leukemia/solid tumors) Clinical study of the safety and efficacy of ponatinib for the treatment of different types of leukemia or solid tumors in children - open for inclusion
Venetoclax M13-833 (hematologic/solid tumors) Clinical study of the safety and efficacy of the drug venetoclax in children and young adults - closed for inclusion
Other trials
Breath analysis (hemato-oncological disease)A clinical pilot study of exhaled breath as an approach in the diagnostic work-up for an invasive fungal infection in the lungs of children with an impaired immune system - open for inclusion
DAVINCY (all cancer types) Clinical study of extended use of the drug (fos)aprepitant to prevent chemotherapy-induced nausea and vomiting - open for inclusion
Dynamic FDG-PET Clinical study to evaluate the use of dynamic FDG-PET scan in pediatric oncology - open for inclusion
FOCUS (all cancer types) Clinical study to optimize dosing of fluconazole in children for the prevention or treatment of invasive fungal infections - open for inclusion
NHL-IgA study (B-NHL) Clinical study of the activity of IgA therapy (antibody therapy) in the laboratory, using blood from children and teenagers with B-cell non-Hodgkin lymphoma (B-NHL) - open for inclusion
PINOCCHIO (multiple types of cancer)Clinical study in children on the metabolism, distribution and excretion of chemotherapy in the body, also called pharmacokinetics - open for inclusion
Tumor donation in Childhood Cancer patients This study is designed to enable post-mortem tumor donation in children that die from all different types of pediatric solid and brain tumors, to enable research on end-stage disease - open for inclusion
VANISH Clinical study of scans of fungal infections in the lungs - open for inclusion
VIKinG (AML & Burkitt lymphoma) Clinical study of the gut microbiota as predictor for bloodstream infections in children with cancer - open for inclusion